scilliroside: structure
scilliroside : A beta-D-glucoside that is scillirosidin in which the hydroxy group at position 3 is substituted by a beta-D-glucopyranoside group. It is a rodenticide extracted from the bulb of the Mediterranean squill plant and was used for the control of Norway rats, black rats, house mice, long-tailed field mice, and field voles.
ID Source | ID |
---|---|
PubMed CID | 441871 |
SCHEMBL ID | 433422 |
MeSH ID | M0079510 |
Synonym |
---|
6-beta-(acetyloxy)-3-beta-(beta-d-glucopyranosyloxy)-8,14-dihydroxybufa-4,20,22-trienolide |
brn 0074900 |
nsc 7523 |
3-beta,6-beta-6-acetyloxy-3-(beta-d-glucopyranosyloxy)-8,14-dihydroxybufa-4,20,22-trienolide |
6beta-(acetyloxy)-3-beta-(beta-d-glucopyranosyloxy)-8,14-dihydroxybufa-4,20,22-trienolide |
bufa-4,20,22-trienolide, 6-(acetyloxy)-3-(beta-d-glucopyranosyloxy)-8,14-dihydroxy- |
3beta-(beta-d-glucopyropyanosyloxy)-6beta,8,14-trihydroxybufa-4,20,22-trienolide 6-accetate |
caswell no. 722 |
scilliroside, (3beta,6beta)- |
bufa-4,20,22-trienolide, 6-(acetyloxy)-3-(beta-d-glucopyranosyloxy)-8,14-dihydroxy-, (3beta,6beta)- |
red squill |
scillirosid |
silmine |
scillirosidin + glucose [german] |
(3beta,6beta)-6-(acetyloxy)-3-(beta-d-glucopyranosyloxy)-8,14-dihydroxybufa-4,20,22-trienolide |
einecs 208-077-4 |
epa pesticide chemical code 070801 |
scilliroside, (3-beta,6-beta)- |
6beta-acetoxy-3beta(beta-d-glucopyranosyloxy)-8,14-dihydroxybufa-4,20,22-trienolide |
silmurin |
scillirosan |
nsc-7523 |
squill |
507-60-8 |
C08880 |
scilliroside |
[(3s,6r,8s,9r,10r,13r,14r,17r)-8,14-dihydroxy-10,13-dimethyl-17-(6-oxopyran-3-yl)-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,6,7,9,11,12,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-6-yl] acetate |
hsdb 6733 |
6-beta-6-(acetyloxy)-3-beta-(beta-d-glocopyranosyloxy)-8,14-dihydroxybufa-4,20,22-trienolide |
(3-beta,6-beta)scilliroside |
2815004nho , |
3-beta,6-beta-6-acetyloxy-3-(beta-d-glocopyranosyloxy)-8,14-dihydroxybufa-4,20,22-trienolide |
unii-2815004nho |
4-18-00-03178 (beilstein handbook reference) |
scillirosidin + glucose |
SCHEMBL433422 |
bufa-4,20,22-trienolide, 6-(acetyloxy)-3-(.beta.-d-glucopyranosyloxy)-8,14-dihydroxy-, (3.beta.,6.beta.)- |
[(3s,6r,8s,9r,10r,13r,14r,17r)-8,14-dihydroxy-10,13-dimethyl-17-(6-oxopyran-3-yl)-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-2,3,6,7,9,11,12,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-6-yl] acetate |
scilliroside [mi] |
DTXSID5042374 |
(3s,6r,8s,9r,10r,13r,14r,17r)-8,14-dihydroxy-10,13-dimethyl-17-(2-oxo-2h-pyran-5-yl)-3-(((2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-6-yl a |
Q7433895 |
Role | Description |
---|---|
rodenticide | A substance used to destroy rodent pests. |
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor | An EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor that interferes with the action of Na(+)/K(+)-transporting ATPase (EC 3.6.3.9). |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
beta-D-glucoside | Any D-glucoside in which the anomeric centre has beta-configuration. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 11 (73.33) | 18.7374 |
1990's | 2 (13.33) | 18.2507 |
2000's | 2 (13.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.88) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (5.56%) | 6.00% |
Case Studies | 1 (5.56%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 16 (88.89%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |